James D. Young

TL;DR: It is shown for the first time that azacitidine and decitabine exhibit different human nucleoside transportability profiles and their cytotoxicities are dependent on the presence of hNTs, which could serve as potential biomarkers of clinical response.

TL;DR: Using high-level expression in E. coli and magic-angle spinning cross-polarization solid-state nuclear magnetic resonance, the binding of the permeant to the protein is measured and its relative mobility within the binding site is assessed, under non-energized conditions, opening the way to elucidating the molecular mechanism of transport in this key family of membrane transporters.

TL;DR: Results suggest that at least two isoforms of the NBMPR-sensitive nucleoside transporter are present in the human placenta, and suggest that the high fetal-placental adenosine uptake previously reported is due to endothelial transporters.

TL;DR: The sugar moiety of nucleosides has been shown to play a major role in permeant‐transporter interaction with human equilibrative nucleoside transporters 1 and 2 and a series of uridine analogs with sugar modifications were subjected to an assay that tested their abilities to inhibit [3H]uridine transport mediated by recombinant hENT1 and hENT2 produced in Saccharomyces cerevisiae.

TL;DR: The renal handling of nucleosides is examined with respect to physiological and clinical implications for the regulation of human kidney NTs and adenosine signaling, intracellular nucleoside transport, and nephrotoxicities associated with some nucleosid drugs.